Neumora Therapeutics, Inc. (NMRA)
| Market Cap | 290.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -293.70M |
| Shares Out | 161.56M |
| EPS (ttm) | -1.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,116,350 |
| Open | 1.720 |
| Previous Close | 1.710 |
| Day's Range | 1.670 - 1.830 |
| 52-Week Range | 1.600 - 21.000 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 20.67 (+1,048.33%) |
| Earnings Date | Mar 6, 2025 |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NMRA stock is "Strong Buy." The 12-month stock price forecast is $20.67, which is an increase of 1,048.33% from the latest price.
News
NMRA Investors are Suing Neumora Therapeutics, Inc.; Contact Robbins LLP for More Information
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutic...
NMRA REMINDER: Kessler Topaz Meltzer & Check, LLP Urges NMRA Investors with Losses to Contact the Firm
RADNOR, Pa. , Feb. 19, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora T...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Neumora To Contact Him Directly To Discuss Their Options If you purchased or acquired...
Neumora Therapeutics Announces Leadership Transition
Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA)
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of N...
Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA
LOS ANGELES--(BUSINESS WIRE)--Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA.
Neumora's depression drug fails trial, sinking shares
CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results.
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Neumora Therapeutics (NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet i...
Neumora Therapeutics' stock craters after trial of major depressive disorder fails to meet main goals
News is a setback for the clinical-stage biotech and a drug that proved successful in earlier trials
Neumora Therapeutics' depression drug fails to meet main goal of late-stage study
Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study.
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo
Neumora: Koastal-1 Readout For MDD Treatment Is First Study On Deck
Neumora Therapeutics is set to release data from the phase 3 KOASTAL-1 study using Navacaprant for the treatment of patients with MDD by the end of 2024; other data in 2025. Navacaprant showed signifi...
This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for majo...
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch – P...
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and ...
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study